Citius Pharmaceuticals
CTXR
13 hedge funds and large institutions have $1.09M invested in Citius Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
30% more funds holding
Funds holding: 10 → 13 (+3)
0.15% less ownership
Funds ownership: 0.24% → 0.09% (-0.15%)
16% less capital invested
Capital invested by funds: $1.3M → $1.09M (-$210K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$65.6K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$60.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$24.3K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$12.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$9.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$813K |
| 2 |
Renaissance Technologies
New York
|
-$55K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$14.4K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$7K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1K |
CTXR Hedge Fund Activity: Q2 2020 in Review
13 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2020, worth a combined $1.09M — down 16% from $1.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CTXR positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $65.6K. The largest seller was Sabby Management, exiting entirely with an estimated $813K sold.
- 13 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2020, up from 10 in Q1 2020.
- Funds reported $1.09M of Citius Pharmaceuticals stock for Q2 2020, down 16% quarter-over-quarter.
- 7 funds opened new Citius Pharmaceuticals positions in Q2 2020 and 4 closed out, a net change of +3 holders.
- The largest Citius Pharmaceuticals buyer in Q2 2020 was Vanguard Group, an estimated $65.6K added.
- The largest Citius Pharmaceuticals seller in Q2 2020 was Sabby Management, an estimated $813K sold.
Based on aggregated 13F filings for Q2 2020.